ClinicalTrials.gg
CompletedNCT05398653Updated Nov 17, 2025

A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

A Phase 1/2 interventional study of MIL62 and Cyclosporine in Primary Membranous Nephropathy, sponsored by Beijing Mabworks Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2022, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Enrollment
23rd of 50
94 · median 77
Started
2022
with 2 others
Phase 1/2
2 of 60
1 open now
Registered
23rd of 60
by date
Lead sponsor
2 of 60
Beijing Mabworks Biotech Co., Ltd.

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 23rd largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 1/2, and was the 23rd registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group. Tolerance to MIL62 was evaluated within 4 weeks after the first administration. If the overall safety is determined by the investigator and sponsor to be tolerable to MIL62, phase II enrollment will be initiated.

The second stage(Phase II) was also randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups according to the ratio of 1:1:1, 20 subjects in each group, to evaluate the efficacy of MIL62 and cyclosporine in the treatment of primary membranous nephropathy. Eligible subjects in both phases received treatment and follow-up for a total of 104 weeks. The primary efficacy endpoints were the 12-week immune remission rate and the 24-week overall remission rate.

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients, ≥18 years of age;
  2. Diagnosis of primary membranous nephropathy (pMN) according to renal prior to or during screening;
  3. Screening 24-hour urinary protein >= 5 g after best supportive care for >= 3 months prior to screening or screening 24-hour urinary protein > 3.5 g after best supportive care for >= 6 months prior to screening, or Screening 24-hour urinary protein > 3.5 g with at least one high-risk factor defined by the protocol;
  4. Estimated (eGFR ) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula ≥40 mL/min/1.73 m\^2;
  5. Sufficient organ function;
  6. Able and willing to provide written and to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a secondary cause of MN
  2. Cyclosporine resistance
  3. Urine protein decreased by > 50% within 6 months before screening
  4. Received treatment drugs for membranous nephropathy
  5. Concomitant with other serious diseases
  6. Received , major surgery (excluding diagnostic procedures), and participated in other clinical trials within 28 days prior to receiving the first study drug
  7. Patients who are positive for surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), with HBV DNA levels above the normal range (HBsAg and/or HBcAb-positive patients require regular HBV DNA testing); patients positive for virus (HCV) antibodies; or patients with a positive (HIV) serology
  8. Participants with \< 300 cells/μL
  9. Those who have a clear history of tuberculosis or have received anti- tuberculosis treatment
  10. Participants with known history of severe allergic reactions to humanized monoclonal antibodies, MIL62, or Cyclosporine
  11. Breastfeeding or pregnant women
  12. and unwillingness or impossibility to comply with a scientifically acceptable birth-control method
  13. Other conditions unsuitable for participation in this study determined by the Investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    MIL62(600mg)

    Drug: MIL62

  • Active comparator
    Ciclosporin

    Drug: Cyclosporine

  • Experimental
    MIL62(1000mg)

    Drug: MIL62

Interventions

  • DrugMIL62

    A 600 mg intravenous (IV) infusion of MIL62 will be administered on Week 1 Day 1 and Week 3 Day 1. If treatment response is observed, additional doses will be administered on Week 25 Day 1 and Week 27 Day 1. According to the protocol amendment in June 2023, some patients also received MIL62 treatment on Week 53 Day 1.

  • Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours. The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached. Optimized cyclosporine dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks.

  • DrugMIL62

    A 1000 mg intravenous (IV) infusion of MIL62 will be administered on Week 1 Day 1 and Week 3 Day 1. If treatment response is observed, additional doses will be administered on Week 25 Day 1 and Week 27 Day 1. According to the protocol amendment in June 2023, some patients also received MIL62 treatment on Week 53 Day 1.

06

What researchers measure

Primary outcomes

  1. Stage 1: The Tolerability and Safety of MIL62 in Participants with Primary Membranous Nephropathy

    Evaluation of the Tolerability and Safety of MIL62 in Participants with pMN.The tolerance is defined as the occurrence of CTCAE 5.0 Grade ≥3 adverse events within 28 days after the first dose of MIL62.Safety assessments included adverse events, vital signs, physical examinations, laboratory tests, Eastern Cooperative Oncology Group (ECOG) performance status and 12-lead electrocardiograms (ECG) during the study period.

    Time frame: up to 2 year after enrollment

  2. Stage 1 and Stage 2: The 12-week immune remission rate in the anti-PLA2R antibody-positive population.

    The proportion of participants who achieved immune remission(Anti-PLA2R antibody\<14RU/mL) at week 12.

    Time frame: Week 12

  3. Stage 1 and Stage 2:The 24-week overall remission rate (ORR)

    The proportion of participants who achieved overall remission (complete and partial remission) at week 24.

    Time frame: week 24

Secondary outcomes

  1. Stage 2: The immune remission rate at week 24, 52, 76, and 104.

    The proportion of participants who achieved immune remissionat week 24, 52, 76, 104.

    Time frame: Week 24, 52, 76 and 104

  2. Stage 2: The complete remission rate (CRR) and partial remission rate (PRR) at week 24.

    The proportion of participants who achieved complete remission (CR) and partial remission (PR) at week 24.

    Time frame: Week 24

  3. Stage 2:The CRR, PRR and ORR at week 52, 76, 104.

    The proportion of participants who achieved CR、PR and overall remission (OR) at week 52,76,104.

    Time frame: Week 52, 76, 104

  4. Stage 2: Time to CR and OR

    Time frame: up to 104 weeks

  5. Stage 2:The duration of CR and OR

    Time frame: up to 104 weeks

  6. Stage 2: Change in anti-PLA2R antibody

    Time frame: up to 104 weeks

  7. Stage 2: Change in eGFR

    Time frame: up to 104 weeks

  8. Stage 2: Change in 24-hour urine protein

    Time frame: up to 104 weeks

  9. Stage 2: Percentage of Participants with Adverse Events (AEs)

    Severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

    Time frame: up to 104 weeks

  10. Stage 2: Percentage of participants with AEs of Special Interest (AESIs)

    Time frame: up to 104 weeks

  11. Stage 2: Peripheral B-cell Counts at Specified Timepoints.

    Time frame: up to 104 weeks

  12. Stage 2: Incidence of ADAs during the study

    Time frame: up to 104 weeks

  13. Stage 2: Pharmacokinetic(PK) Parameters during the study: Area Under the Curve(AUC)

    Time frame: up to 104 weeks

  14. Stage 2: Pharmacokinetic(PK) Parameters during the study:Maximum Concentration(Cmax)

    Time frame: up to 104 weeks

  15. Stage 2: Pharmacokinetic(PK) Parameters during the study: t1/2

    Time frame: up to 104 weeks

  16. Stage 2: Pharmacokinetic(PK) Parameters during the study: Volume of Distribution (Vd)

    Time frame: up to 104 weeks

  17. Stage 2: Pharmacokinetic(PK) Parameters during the study: Clearance(CL)

    Time frame: up to 104 weeks

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Mar 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 1, 2022
StartActual
Feb 24, 2022
Primary completionActual
Mar 4, 2025
CompletionActual
Apr 18, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05398653
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Feb 24, 2022
Primary completion
Mar 4, 2025
Completion
Apr 18, 2025
Last update
Nov 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Monoclonal Antibody MIL62

Start the discussion